There are 3397 resources available
1375P - Beamion Lung 1, an ongoing phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients (pts) with advanced solid tumors with HER2 aberrations: Latest data
Presenter: Frans Opdam
Session: Poster session 20
1377P - Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity
Presenter: Xiuning Le
Session: Poster session 20
1378P - Efficacy and safety of tunlametinib (HL-085) combined with vemurafenib in patients with advanced BRAF V600-mutated solid tumors: A multicenter, phase I study
Presenter: Yuan-Kai Shi
Session: Poster session 20
1379P - Preliminary results of phase II KUNPENG study of vebreltinib in patients (Pts) with advanced NSCLC harboring c-MET alterations
Presenter: Jin-Ji Yang
Session: Poster session 20
1380P - Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial
Presenter: Santiago Viteri
Session: Poster session 20
1381P - TOGETHER: Pooled real-world datasets of METex14 skipping NSCLC and adjusted comparison of upfront (chemo-)immunotherapy with tepotinib from VISION
Presenter: Petros Christopoulos
Session: Poster session 20
1382P - Liquid biopsies (LBx) and tissue biopsies (TBx) for identifying MET exon 14 (METex14) skipping in advanced NSCLC: Analyses from the phase II VISION study of tepotinib
Presenter: Christian Rolfo
Session: Poster session 20
1383P - Efficacy of capmatinib compared to standard of care for German patients with locally advanced or metastatic NSCLC harboring METex14 mutations: Results from the RECAP study
Presenter: Anna Kron
Session: Poster session 20
1384P - Phase II study of cabozantinib in patients with MET-altered lung cancers
Presenter: Guilherme Harada
Session: Poster session 20
1385P - Genomics of early progression on selpercatinib in patients with RET fusion-positive lung cancers
Presenter: Monica Chen
Session: Poster session 20